Table 3. Antimicrobial resistance patterns of E. coli isolates by ESBL positivity.
| Antibiotic | ESBL E. coli (n = 51) | Non-ESBL E. coli (n = 28) | ||||
|---|---|---|---|---|---|---|
| S | I | R | S | I | R | |
| Amoxicillin/Clavulanic acid | 28 (56%) | 18 (36%) | 4 (8%) | 26 (92.9%) | 2 (7.1%) | - |
| Cefuroxime | 10 (20%) | 1 (2%) | 39 (78%) | 25 (89.3%) | 1 (3.6%) | 2 (7.1%) |
| Ceftriaxone | 13 (26%) | 2 (4%) | 35 (70%) | 24 (88.9%) | 1 (3.7%) | 2 (7.4%) |
| Piperacillin/Tazobactam | 43 (86%) | 3 (6%) | 4 (8%) | 25 (96.2%) | - | 1 (3.8%) |
| Gentamicin | 34 (66.7%) | - | 17 (33.3%) | 28 (100%) | - | - |
| Nalidixic acid | 7 (14%) | - | 43 (86%) | 11 (39.3%) | - | 17 (60.7%) |
| Ciprofloxacin | 21 (41.2%) | 1 (2.0%) | 29 (56.9%) | 20 (71.4%) | 1 (3.6%) | 7 (25%) |
| Meropenem | 51 (100%) | - | - | 28 (100%) | - | - |
| Nitrofurantoin | 48 (96%) | 1 (2.0%) | 1 (2.0%) | 25 (89.3%) | 2 (7.1%) | 1 (3.6%) |
| Trimethoprim/sulfamethoxazole | 23 (45.1%) | - | 28 (54.9%) | 20 (76.9%) | - | 6 (23.1%) |
| Multi-drug resistant (≥3 classes) | 23 (45.1%) | 0 | ||||